Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HMFG2-131I
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**HMFG2-131I** is a radiolabeled monoclonal antibody therapy in which the mouse monoclonal antibody HMFG2 is conjugated to radioactive iodine-131. HMFG2 specifically targets the MUC1 glycoprotein, an antigen overexpressed on the surface of many epithelial cancers, including breast and ovarian cancer. By labeling HMFG2 with Iodine-131, the combination delivers cytotoxic beta radiation directly to MUC1-expressing tumor cells, thereby enabling both tumor imaging (immunoscintigraphy) and selective radiotherapeutic destruction. This approach is intended to improve the detection and treatment of local and metastatic disease with increased tumor specificity compared to conventional systemic radioisotope therapies. It is primarily developed for the preoperative detection and adjuvant treatment of breast cancer and has been investigated in clinical studies for these purposes[4].
- Other names
- 131I-HMFG2131I-labelled HMFG2
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on HMFG2-131I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HMFG2-131I.